Retrospective Multicenter Observational Study to Evaluate... | EligiMed

Retrospective Multicenter Observational Study to Evaluate Safety and Effectiveness of Bevacizumab (Avastin®) in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Patients With Advanced Cervical Cancer

CompletadoClinicalTrials.gov

ID: NCT03071848Tipo: OBSERVATIONALInicio: 6 de abr de 2017Fin estimado: 20 de dic de 2017

Traducción no disponible, mostrando original

Resumen

This study will evaluate the safety of bevacizumab (Avastin®) combined with standard chemotherapy in participant with advanced cervical cancer, with special focus on the incidence of gastrointestinal (GI) and genitourinary (GU) fistulas and GI perforations in the common practice setting.

Elegibilidad

Edad mínima: 18 YearsSexo: FEMALE

Criterios de inclusión

Age 18 or older
Diagnosis of primary stage IVB, recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy
Retrospective clinical decision made to initiate therapy with bevacizumab (Avastin®) combined with standard chemotherapy (cisplatin or carboplatin or topotecan and paclitaxel) between 01 January 2015 and 01 January 2016
All participants must have received at least one dose of bevacizumab combined with standard chemotherapy between 01 January 2015 and 01 January 2016 AND have at least 12 months of documented follow up, from treatment start, unless died or lost to follow up within the minimum study entry follow up period
Availability of documentation of for advanced cervical cancer (including prior treatment as applicable) and follow up in the participant's medical records

Criterios de exclusión

Participation during the study period in an interventional clinical trial or any other interventional study that may impact advanced cervical cancer outcome
Participants who have received prior therapy with any anti-VEGF drug, including bevacizumab

Intervenciones

other

No Intervention

This was an observational study.

Ubicaciones

Hospital General de Agudos Juan Antonio Fernandez

Buenos Aires, Argentina

Hospital General de Agudos J. A. Penna ; Breast Pathology

Buenos Aires, Argentina

Instituto Ángel H. Roffo - Universidad de Buenos Aires

Buenos Aires, Argentina

Hospital Julio C. Perrando

Chaco, Argentina

Centro Oncologico Riojano Integral (CORI)

La Rioja, Argentina

Hospital Interzonal General De Agudos "Luisa C. de Gandulfo"

Lomas de Zamora, Argentina

Hospital Privado de Comunidad; Oncology

Mar del Plata, Argentina

Hosp Provincial D. Centenarios; Oncology Dept

Rosario, Argentina

CENICLAR

Rosario, Argentina

Policlínico regional de San Luis

San Luis, Argentina

Centro Medico San Roque

San Miguel de Tucumán, Argentina

Hospital Pablo Soria

San Salvador de Jujuy, Argentina

Patrocinadores

PrincipalHoffmann-La Roche

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.